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MammaryCD24 is an anchored cell surface marker that is highly expressed in cancer cells (Lee et al., 2009) and its expres-
sion is associated with poorer outcome of cancer patients (Kristiansen et al., 2003). Phenotype comparison
between two subpopulations derived from theMvt1 cell line, CD24− cells (with no CD24 cell surface expression)
and the CD24+ cells, identiﬁed high tumorigenic capacity for the CD24+ cells. In order to reveal the transcripts
that support the CD24+ aggressive and invasive phenotype we compared the gene proﬁles of these two subpop-
ulations. mRNA proﬁles of CD24− and CD24+ cells were generated by deep sequencing, in triplicate, using an
Illumina HiSeq 2500. Here we provide a detailed description of the mRNA-seq analysis from our recent study
(Rostoker et al., 2015). The mRNA-seq data have been deposited in the NCBI GEO database (accession number
GSE68746).helial m
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r mRNA
4+ cells
. This is© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ammary carcinoma
expression analysis1. Direct link to deposited data
Deposited data can be found here: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE68746.an open access article under2. Experimental design, materials and methods
Expression of CD24, an anchored cell surface marker, is associated
with poorer outcome in cancer patients [1,2]. We used mRNA-seq to
identify transcripts that are differentially expressed in CD24+ cells
compared to CD24− cells [3].
2.1. Cell culture and cell sorting
The Mvt1 mammary cancer cells [4] were cultured in DMEM
supplemented with 10% fetal bovine serum and antibiotics
(penicillin:streptomycin) at 37 °C in a humidiﬁed atmosphere consisting
of 5% CO2 and 95% air.
Mvt1 cells were cell surface stained for CD24 expression and sorted
into two separate groups of cells, CD24− and CD24+ cells using the
FACSAria.
2.2. Experimental design and total RNA preparation
Total RNA was isolated and puriﬁed from 3 different plates (each
group) of adherent cells grown in DMEM supplemented with 10%
fetal bovine serum using the Total RNA Puriﬁcation Kit (Norgen Biotek
Corp) according to the manufacturer's instructions. RNA quality wasthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
400 R. Rostoker et al. / Genomics Data 5 (2015) 399–401assessed by the RNA analysis screentape (R6K screentape, Agilent), RNA
with RIN N 9 was reverse transcribed to cDNA. cDNA libraries were
prepared using 1 μg of total RNA using the TruSeq RNA Sample Prepara-
tion Kit v2 (Illumina).
2.3. mRNA-seq and data analysis
cDNA libraries were sequenced on the IlluminaHiSeq 2500 platform
to obtain 51-bp single-end reads. The reads were trimmed, 2 nt on each
end, to remove low quality parts, and improve mapping to the genome.
The 47 nt reads that resulted were compressed by removing duplicates,
but keeping track of how many times each sequence occurred in each
sample in a database. The unique reads were then mapped to the
mouse genome, using exact matches. This misses reads that cross
exon–exon boundaries, as well as reads with errors and SNPs/
mutations, but it does not have substantial impact on estimating the
levels of expression of each gene. Each mapped read was then assigned
annotations from the underlying genome. In case of multiple annota-
tions (e.g. a miRNA occurring in the intron of a gene), a hierarchy
based on heuristics was used to give a unique identity to each read.
This was then used to identify the reads belonging to each transcript
and coverage over each position on the transcript was established.
This coverage is non-uniform and spiky, thus we used the median of
this coverage as an estimate of the gene's expression value. In order to
compare the expression in different samples, quantile normalization
was used. The ratios of expression levels were then calculated to esti-
mate the log (to base 2) of the fold-change. In order to prevent low-
expressed genes from dominating the list of genes with a large fold
change, we added a regularizer (10) to each value, ensuring that
genes with expression around or below 10 would appear to have low
fold-change [5,6]. We did gene set enrichment analysis using theA B
Fig. 1. Enrichment in ECM and collagens in the tumorigenic CD24+ subset. A, Gene set enrich
~erans/cancer/modules/module_47.html). B, Heat map illustrating gene expression from the mGSEA software. Of all the cancer modules that we tested our expression
against, we found that module 47 was signiﬁcantly up-regulated in the
CD24 positive populations (Fig. 1A). Extracellular matrix proteins and
collagens were enriched in this module with an FDR corrected p-value
of 0.05 (Fig. 1B).
3. Discussion
The CD24+Mvt1 subset displays highly tumorigenic and metastatic
capacity compared to their CD24− counterparts [3]. Taking advantage of
the Illumina HiSeq 2500 we preformed transcript analysis in order to
compare between the gene proﬁles of these two subsets. Ting DT et al.
recently found that elevated expression in ECM (extracellular matrix)
genes is common in different types of circulating cancer cells [7].
These results suggest that elevated expression of ECM transcripts
promote cancer cell capacity to drive not only tumors at the primary
site but also at distant organs.
These ECM components enable cancer cells to remodel the host
tissue in order to form ‘metastatic niche’ by acting and responding to
the surrounding host tissue cells [8]. In our recent study, we found
that CD24+ Mvt-1 form rapidly mammary tumors, moreover, with the
tail vein assay, our results demonstrated metastatic phenotype of
these CD24+ cells [3]. Similar to Ting DT et al. results, our gene analysis
highlighted high expression of ECM genes in this CD24+ aggressive
subset (Fig. 1). This gene proﬁle may reveal new mechanisms in
tumorigenesis and can serve as a start point for further research with
an important clinical implication for metastatic tumors.
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